KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

por Hamidi, H, Lu, M, Chau, K, Anderson, L, Fejzo, M, Ginther, C, Linnartz, R, Zubel, A, Slamon, D J, Finn, R S
Publicado 2014

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

por Konecny, G E, Venkatesan, N, Yang, G, Dering, J, Ginther, C, Finn, R, Rahmeh, M, Fejzo, M Schoenberg, Toft, D, Jiang, S-W, Slamon, D J, Podratz, K C
Publicado 2008

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

por Konecny, G E, Glas, R, Dering, J, Manivong, K, Qi, J, Finn, R S, Yang, G R, Hong, K-L, Ginther, C, Winterhoff, B, Gao, G, Brugge, J, Slamon, D J
Publicado 2009

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

por Rugo, H S, Diéras, V, Gelmon, K A, Finn, R S, Slamon, D J, Martin, M, Neven, P, Shparyk, Y, Mori, A, Lu, D R, Bhattacharyya, H, Bartlett, C Huang, Iyer, S, Johnston, S, Ettl, J, Harbeck, N
Publicado 2018

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

por Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. Huang, Gelmon, K. A., Slamon, D. J.
Publicado 2019

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

por Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D. J.
Publicado 2023